AAP
XENE icon

Arax Advisory Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Arax Advisory Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.6K Buy
+441
New +$24.5K ﹤0.01% 3761
2026
Q1 		– Sell
-27
Closed -$1.21K – 4380
2025
Q4 		$1.21K Sell
27
-92
-77% -$3.86K ﹤0.01% 3436
2025
Q3 		$4.78K Buy
+119
New +$4.19K ﹤0.01% 2886
2024
Q4 		– Sell
-3
Closed -$119 – 2781
2024
Q3 		$119 Hold
3
– – ﹤0.01% 2547
2024
Q2 		$117 Buy
+3
New +$120 ﹤0.01% 2482

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Arax Advisory Partners's XENE Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 441 shares worth $26.6K. The stake represents ﹤0.01% of the portfolio and ranks #3761 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in XENE as recently as Q4 2025.

Arax Advisory Partners first reported a position in XENE in Q2 2024 and has held it in 5 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Arax Advisory Partners held 441 shares of Xenon Pharmaceuticals worth $26.6K as of Q2 2026.
  • Xenon Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3761 holding.
  • Arax Advisory Partners first reported a position in Xenon Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.